Actively Recruiting

Phase 4
Age: 18Years - 75Years
All Genders
NCT06560801

Dapagliflozin on Renal Morphology and Renal Perfusion in Patients One Year After Kidney Transplantation

Led by University of Erlangen-Nürnberg Medical School · Updated on 2026-05-06

48

Participants Needed

1

Research Sites

178 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The aim of this study is to observe the mechanisms of dapagliflozin on the renal interstitial tissue and renal perfusion. For this purpose, renal transplanted patients as an excellent model of CKD and high cardiovascular risk (similar to patients in DAPA-CKD study) are included in this study. The objectives of the study are to analyze the effects of dapagliflozin on renal morphology and renal perfusion in patients with impaired renal function one year after kidney transplantation. This is a randomized (1:1), single centre clinical study. Each patient will be randomly assigned in an unblinded fashion to 10 mg Dapagliflozin or not 9 months after transplantation. At least 48 patients will be randomized and included. The routine renal biopsy taken one year after kidney transplantation will allow us to determine the morphological integrity of peritubular fibroblasts, interstitial inflammatory cell density and investigate markers of inflammation, oxidative stress and nitic oxide synthase expression (iNOS).

CONDITIONS

Official Title

Dapagliflozin on Renal Morphology and Renal Perfusion in Patients One Year After Kidney Transplantation

Who Can Participate

Age: 18Years - 75Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Female and male patients aged between 18 and 75 years
  • Patients with renal transplant having a stable eGFR, who are in stable condition, 9 months after transplantation, irrespective of their diabetes status
  • Females of child bearing potential must be using adequate contraceptive precautions
  • Females of childbearing potential or within two years of the menopause must have a negative urine pregnancy test at screening visit
  • Informed consent has to be given in written form
Not Eligible

You will not qualify if you...

  • Type 1 diabetes mellitus
  • HbA1c > 10%
  • Use of SGLT-2 inhibitor within the past 2 months
  • Any history of stroke, transient ischemic attack, unstable angina pectoris, or myocardial infarction within the last 3 months prior to study inclusion
  • eGFR <25 ml/min/1.73m² (CKD-EPI Formula)
  • Uncontrolled arterial hypertension (blood pressure > 180/110 mmHg)
  • Congestive heart failure NYHA stage IV
  • Recurrent urinary tract infections (bacterial or fungal)
  • Severe disorders of the gastrointestinal tract or other diseases which interfere with the drug's effects
  • Significant laboratory abnormalities such as SGOT or SGPT levels more than 5 times the upper limit of normal
  • Pregnant or breast-feeding patients
  • Patients with contraindications to MRI
  • Drug or alcohol abuse

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Clinical Research Center (CRC)

Erlangen, Bavaria, Germany, 91054

Actively Recruiting

Loading map...

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here